New drug shows promise against hard-to-treat blood cancer

Teclistamab offers hope for multiple myeloma patients who have exhausted standard treatments, according to a major clinical trial. The finding could reshape treatment strategies and expand the market for next-generation cancer therapies targeting resistant disease.

Originaltitel: Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma